EGFR and non-small cell lung carcinoma: With the significant duration of the response and improved OS compared with the standard TKI regimen that was documented in the FLAURA trial [22,23], the FDA approved osimertinib as a first-line treatment for late-stage EGFR-mutant NSCLC.